Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells

International Journal of Cancer

Volumn 126, Issue 11, 2010, Pages 2520-2533

  Pandey, Mitali ^a   Shukla, Sanjeev ^a   Gupta, Sanjay ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Chemoprevention; DNA methylation; Epigenetics; GSTP1; Histone modification; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; HISTONE H4; MESSENGER RNA; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 1; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 4; POLYPHENOL DERIVATIVE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; FLAVONOID; GSTP1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATE; HISTONE; IMMUNOGLOBULIN; PHENOL DERIVATIVE; POLYPHENOLS; SP1 ANTIGEN;

ARTICLE; BINDING SITE; CANCER CELL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; TEA; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPITHELIAL CELLS; FLAVONOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUTATHIONE S-TRANSFERASE PI; GUANOSINE TRIPHOSPHATE; HISTONES; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; MALE; PHENOLS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TEA;

EID: 77951225012     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24988     Document Type: Article

References (50)

1. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159:1815-1826 (Pubitemid 33062524)
2. Singal R, van Wert J, Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 2001;61:4820-4826 (Pubitemid 32691897)
3. Henderson CJ, Mclaren AW, Moffat GJ, Bacon EJ, Wolf CR. Pi-class glutathione S-transferase: regulation and function. Chem Biol Interact 1998;111-112:69-82. (Pubitemid 28271935)
4. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S- transferase family of enzymes. Mutat Res 2001;482:21-26
5. Gsur A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 2001;95:152-155 (Pubitemid 32477229)
6. Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, Wolf CR. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 1998;95:5275-5280 (Pubitemid 28208588)
7. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR. Glutathione-S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003;63:8097-8102 (Pubitemid 37549452)
8. Chen CL, Sheen TS, Lou IU, Huang AC. Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma. Hum Pathol 2001;32:1240-1244 (Pubitemid 33104436)
9. Moffat GJ, Mclaren AW, Wolf CR. Sp1-mediated transcriptional activation of the human Pi class glutathione-S-transferase promoter. J Biol Chem 1996;271:1054-1060 (Pubitemid 26034965)
10. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione-S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999;18:1313-1324 (Pubitemid 29094883)
11. Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate 2002;51:225-230 (Pubitemid 34556372)
12. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:540-552
13. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163:923-933 (Pubitemid 37040128)
14. Hopkins TG, Burns PA, Routledge MN. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 2007;69:11-16
15. Ptak C, Petronis A. Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Pharmacol Toxicol 2008;48:257-276 (Pubitemid 351738154)
16. Siedlecki P, Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim Pol 2006;53:245-256
17. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007;12:4254-4266
18. Morey SR, Smiraglia DJ, James SR, Yu J, Moser MT, Foster BA, Karpf AR. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res 2006;66:11659-11667 (Pubitemid 46094177)
19. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005;97:1498-1506 (Pubitemid 41631949)
20. Mccabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006; 66:385-392 (Pubitemid 43166046)
21. Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-20-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-11801 (Pubitemid 24985095)
22. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560-6565
23. Rehman I, Goodarzi A, Cross SS, Leiblich A, Catto JW, Phillips JT, Hamdy FC. DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. Prostate 2007;67:341-347 (Pubitemid 46341075)
24. Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 2003;17:1081-1088 (Pubitemid 36676394)
25. Chen D, Milacic V, Chen MS, Wan SB, Lam WH, Huo C, Landis-Piwowar KR, Cui QC, Wali A, Chan TH, Dou QP. Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol 2008;23:487-496 (Pubitemid 351552334)
26. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol(-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-2505
27. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgensensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000;164:82-90. (Pubitemid 30198547)
28. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-7570 (Pubitemid 37466673)
29. Millar DS, Paul CL, Molloy PL, Clark SJ. A distinct sequence (ATAAA)n separates methylated and unmethylated domains at the 50-end of the GSTP1 CpG island. J Biol Chem 2000;275:24893-24899
30. Prokhortchouk E, Hendrich B. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 2002;21:5394-5399
31. Lin X, Nelson WG. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 2003;63:498-504. (Pubitemid 36152513)
32. Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem 2002;277:22573-22580 (Pubitemid 34967234)
33. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001;287:705-713 (Pubitemid 32912772)
34. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-162
35. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005;24:7213-7223 (Pubitemid 41679283)
36. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, Dileone L, Mans DR. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest N Drugs 2000;18:83-91. (Pubitemid 30175899)
37. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321:591-599 (Pubitemid 36124798)
38. Kuzuhara T, Sei Y, Yamaguchi K, Suganuma M, Fujiki H. DNA and RNA as new binding targets of green tea catechins. J Biol Chem 2006;281:17446-17456 (Pubitemid 43909552)
39. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002;21:5496-5503 (Pubitemid 34983484)
40. Okino ST, Pookot D, Majid S, Zhao H, Li LC, Place RF, Dahiya R. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol Carcinog 2007;46:839-846 (Pubitemid 47549769)
41. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007;211:269-277 (Pubitemid 46172702)
42. Florl AR, Steinhoff C, Müller M, Seifer HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004;91:985-994 (Pubitemid 39273795)
43. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, Speights VO, Isaac J, Rohr LR. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005;156:31-36
44. Karpf AR. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther 2007;9:231-241
45. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97:103-115 (Pubitemid 40277090)
46. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003;95:1747-1757
47. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98:10350-10355 (Pubitemid 32803023)
48. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S; JPHC Study Group. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71-77
49. Zhang M, Holman CD, Huang JP, Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis 2007;28:1074-1078 (Pubitemid 47072193)
50. Larsson SC, Wolk A. Tea consumption and ovarian cancer risk in a population-based cohort. Arch Intern Med 2005;165:2683-2686 (Pubitemid 41785069)